Artificial intelligence and machine learning techniques are breaking into biomedical
research and health care, which importantly includes cancer research and oncology, where�…

Basic science breakthroughs in T-cell biology and immune–tumor cell interactions ushered
in a new era of cancer immunotherapy. Twenty years ago, cancer immunoediting was�…

Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat
non-small cell lung cancer (NSCLC) patients, based on their significant overall survival (OS)�…

With the burgeoning use of immune-based treatments for cancer, never has there been a
greater need to understand the tumour microenvironment within which immune cells�…

Currently, immune checkpoint blockade (ICB) therapies that target the programmed cell
death ligand-1 (PD-L1) have been used as revolutionary cancer treatments in the clinic�…

As our understanding of the mechanisms of cancer treatment has increased, a growing
number of studies demonstrate pathways through which DNA damage repair (DDR) affects�…

Introduction Despite the many benefits immunotherapy has brought to patients with different
cancers, its clinical applications and improvements are still hindered by drug resistance�…

As a breakthrough strategy for cancer treatment, immunotherapy mainly consists of immune
checkpoint inhibitors (ICIs) and other immunomodulatory drugs that provide a durable�…

Tumour dendritic cells (DCs) internalise antigen and upregulate CCR7, which directs their
migration to tumour-draining lymph nodes (dLN). CCR7 expression is coupled to an�…

Efficiently reawakening immune cells, including T cells and macrophages, to eliminate tumor
cells is a promising strategy for cancer treatment, but remains a huge challenge nowadays�…